BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29791894)

  • 1. Highly Tumorigenic Diffuse Large B Cell Lymphoma Cells Are Produced by Coculture with Stromal Cells.
    Lin Z; Chen B; Wu T; Xu X
    Acta Haematol; 2018; 139(4):201-216. PubMed ID: 29791894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation.
    Tsai HJ; Shih NY; Kuo SH; Cheng AL; Lin HY; Chen TY; Chang KC; Lin SF; Chang JS; Chen LT
    Leuk Lymphoma; 2015; 56(9):2674-82. PubMed ID: 25535814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological DNA demethylation restores SMAD1 expression and tumor suppressive signaling in diffuse large B-cell lymphoma.
    Stelling A; Wu CT; Bertram K; Hashwah H; Theocharides APA; Manz MG; Tzankov A; Müller A
    Blood Adv; 2019 Oct; 3(20):3020-3032. PubMed ID: 31648327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.
    Bongero D; Paoluzzi L; Marchi E; Zullo KM; Neisa R; Mao Y; Escandon R; Wood K; O'Connor OA
    Leuk Lymphoma; 2015; 56(10):2945-52. PubMed ID: 25860245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
    Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
    EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
    Feng L; Xu X; Zhao K
    Leuk Res; 2021 Dec; 111():106708. PubMed ID: 34536775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.
    Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J
    Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
    Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
    Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.
    Xu ZZ; Wang WF; Fu WB; Wang AH; Liu ZY; Chen LY; Guo P; Li JM
    Leuk Lymphoma; 2014 May; 55(5):1151-7. PubMed ID: 23841505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.
    Xu PP; Sun YF; Fang Y; Song Q; Yan ZX; Chen Y; Jiang XF; Fei XC; Zhao Y; Leboeuf C; Li B; Wang CF; Janin A; Wang L; Zhao WL
    Sci Rep; 2017 Aug; 7(1):7433. PubMed ID: 28785100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
    Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
    Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.
    Mathur R; Sehgal L; Havranek O; Köhrer S; Khashab T; Jain N; Burger JA; Neelapu SS; Davis RE; Samaniego F
    Haematologica; 2017 Feb; 102(2):373-380. PubMed ID: 27742770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin.
    Sun N; Wang CY; Sun YQ; Ruan YJ; Huang YY; Su T; Zhou XH; Huang H; Guo WJ; He MQ; Yao RX; Lin XJ
    Biomed Pharmacother; 2018 Oct; 106():267-274. PubMed ID: 29966970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of chemokines in diffuse large B-cell lymphoma: a systematic review and future insights.
    Huang Q; Liu F; Shen J
    Future Oncol; 2019 Apr; 15(12):1385-1395. PubMed ID: 30880459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
    Lv X; Feng L; Ge X; Lu K; Wang X
    J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
    J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.
    Xu ZZ; Fu WB; Jin Z; Guo P; Wang WF; Li JM
    Leuk Lymphoma; 2016; 57(4):888-98. PubMed ID: 26415087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
    Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
    Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
    Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
    Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
    Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
    J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.